# TYSABRI and Vaccinations
Keywords: TYSABRI, SARS-CoV-2, MS, Multiple Sclerosis, RRMS, Disease-Modifying Therapy, COVID-19 vaccines, vaccination safety

> This page provides information about the use of TYSABRI in relation to vaccinations, particularly SARS-CoV-2 vaccines, and their impact on patients with Multiple Sclerosis (MS), including safety, efficacy, and observed responses.

## Details
- [SARS-CoV-2 vaccines for people with MS](#): Overview of vaccine safety and effectiveness for individuals with MS, including temporary symptom worsening and observed responses in patients treated with TYSABRI.
- [IRR of SARS-CoV-2 infection among MS patients receiving DMTs](#): Analysis of infection rates among MS patients on Disease-Modifying Therapies compared to the general population, showing similar protection for TYSABRI-treated patients.
- [References & abbreviations](#): Definitions of key terms and references to studies related to MS, SARS-CoV-2 vaccines, and TYSABRI.
- [Adverse event reporting](#): Information on how healthcare professionals can report adverse events in the UK and Ireland.